Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CSF1R | P07333 | 20/20 | 0.59 |
| ▸ | PDGFRA | P16234 | 13/20 | 0.59 |
| ▸ | PDGFRB | P09619 | 7/20 | 0.59 |
| ▸ | FLT3 | P36888 | 4/20 | 0.59 |
| ▸ | CYP2C9 | P11712 | 2/20 | 0.59 |
| ▸ | KDR | P35968 | 2/20 | 0.58 |
| ▸ | KIT | P10721 | 2/20 | 0.58 |
| ▸ | LCK | P06239 | 1/20 | 0.58 |
| ▸ | PTK6 | Q13882 | 1/20 | 0.58 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30022723 | 1.00 | CSF1R (0.59) | CSF1RPDGFRAPDGFRBFLT3CYP2C9 | |
| SCHEMBL16028873 | 0.92 | CSF1R (0.52) | CSF1RPDGFRAPDGFRBFLT3CYP2C9 | |
| SCHEMBL16085814 | 0.89 | CSF1R (0.48) | CSF1RPDGFRAPDGFRBFLT3CYP2C9 | |
| SCHEMBL21425617 | 0.88 | CSF1R (0.61) | CSF1RPDGFRAPDGFRBFLT3CYP2C9 | |
| SCHEMBL16029505 | 0.87 | CSF1R (0.61) | CSF1RPDGFRAPDGFRBFLT3CYP2C9 | |
| SCHEMBL28893618 | 0.86 | CSF1R (0.59) | CSF1RPDGFRAPDGFRBFLT3CYP2C9 | |
| SCHEMBL21772028 | 0.86 | CSF1R (0.49) | CSF1RPDGFRAPDGFRBFLT3CYP2C9 | |
| SCHEMBL21425566 | 0.86 | CSF1R (0.51) | CSF1RPDGFRAPDGFRBFLT3CYP2C9 | |
| SCHEMBL21425571 | 0.86 | CSF1R (0.51) | CSF1RPDGFRAPDGFRBFLT3CYP2C9 | |
| SCHEMBL16028718 | 0.86 | CSF1R (0.59) | CSF1RPDGFRAPDGFRBFLT3CYP2C9 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 53 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250361223-A1 | AMIDE COMPOUNDS AND USES THEREOF | HUTCHISON MEDIPHARMA LTD (CN) | 2025-11-27 | — | — | US | disclosed |
| US-12435062-B2 | Amide compounds and uses thereof | HUTCHISON MEDIPHARMA LIMITED (CN) | 2025-10-07 | — | — | US | disclosed |
| US-20240317710-A1 | CRYSTALLINE CSF-1R INHIBITOR ACIDIC SALT, PREPARATION METHOD THEREFOR AND USE THEREOF | ABBISKO THERAPEUTICS CO., LTD. (CN) | 2024-09-26 | — | — | US | disclosed |
| EP-4349827-A1 | ACID SALT OF CRYSTALLINE CSF-1R INHIBITOR, AND PREPARATION METHOD THEREFOR AND USE THEREOF | Abbisko Therapeutics Co., Ltd. (CN) | 2024-04-10 | — | — | EP | disclosed |
| CN-117777103-A | Amide compound and application thereof | 和记黄埔医药（上海）有限公司 | 2024-03-29 | — | — | CN | disclosed |
| CN-117720520-A | Amide compound and application thereof | 和记黄埔医药（上海）有限公司 | 2024-03-19 | — | — | CN | disclosed |
| CN-117720519-A | Amide compound and application thereof | 和记黄埔医药（上海）有限公司 | 2024-03-19 | — | — | CN | disclosed |
| EP-3632907-B1 | N-(AZAARYL)CYCLOLACTAM-1-CARBOXAMIDE DERIVATIVE, PREPARATION METHOD THEREFOR, AND USE THEREOF | ABBISKO THERAPEUTICS CO LTD (CN) | 2024-02-28 | — | — | EP | disclosed |
| EP-3632907-B1 | N-(AZAARYL)CYCLOLACTAM-1-CARBOXAMIDE DERIVATIVE, PREPARATION METHOD THEREFOR, AND USE THEREOF | ABBISKO THERAPEUTICS CO LTD (CN) | 2024-02-28 | — | — | EP | disclosed |
| CN-115315422-B | Amide compound and application thereof | 和记黄埔医药（上海）有限公司 | 2023-11-07 | — | — | CN | disclosed |
| US-20140315917-A1 | IMIDAZOLIDINONES AND ANALOGS EXHIBITING ANTI-CANCER AND ANTI-PROLIFERATIVE ACTIVITIES | DECIPHERA PHARMACEUTICALS, LLC (US) | 2014-10-23 | — | — | US | disclosed |
| US-20140315917-A1 | IMIDAZOLIDINONES AND ANALOGS EXHIBITING ANTI-CANCER AND ANTI-PROLIFERATIVE ACTIVITIES | DECIPHERA PHARMACEUTICALS, LLC (US) | 2014-10-23 | — | — | US | disclosed |
| US-20140315917-A1 | IMIDAZOLIDINONES AND ANALOGS EXHIBITING ANTI-CANCER AND ANTI-PROLIFERATIVE ACTIVITIES | DECIPHERA PHARMACEUTICALS, LLC (US) | 2014-10-23 | — | — | US | disclosed |
| US-20140275080-A1 | N-Acyl-N'-(pyridin-2-yl) Ureas and Analogs Exhibiting Anti-Cancer and Anti-Proliferative Activities | DECIPHERA PHARMACEUTICALS, LLC (US) | 2014-09-18 | — | — | US | disclosed |
| US-20140275080-A1 | N-Acyl-N'-(pyridin-2-yl) Ureas and Analogs Exhibiting Anti-Cancer and Anti-Proliferative Activities | DECIPHERA PHARMACEUTICALS, LLC (US) | 2014-09-18 | — | — | US | disclosed |
| US-20140275080-A1 | N-Acyl-N'-(pyridin-2-yl) Ureas and Analogs Exhibiting Anti-Cancer and Anti-Proliferative Activities | DECIPHERA PHARMACEUTICALS, LLC (US) | 2014-09-18 | — | — | US | disclosed |
| WO-2014145028-A2 | N-ACYL-N'-(PYRIDIN-2-YL) UREAS AND ANALOGS EXHIBITING ANTI-CANCER AND ANTI-PROLIFERATIVE ACTIVITIES | DECIPHERA PHARMACEUTICALS, LLC (US) | 2014-09-18 | — | — | WO | disclosed |
| WO-2014145015-A2 | IMIDAZOLIDINONES AND ANALOGS EXHIBITING ANTI-CANCER AND ANTI-PROLIFERATIVE ACTIVITIES | DECIPHERA PHARMACEUTICALS, LLC (US) | 2014-09-18 | — | — | WO | disclosed |
| WO-2014145028-A2 | N-ACYL-N'-(PYRIDIN-2-YL) UREAS AND ANALOGS EXHIBITING ANTI-CANCER AND ANTI-PROLIFERATIVE ACTIVITIES | DECIPHERA PHARMACEUTICALS, LLC (US) | 2014-09-18 | — | — | WO | disclosed |
| WO-2014145015-A2 | IMIDAZOLIDINONES AND ANALOGS EXHIBITING ANTI-CANCER AND ANTI-PROLIFERATIVE ACTIVITIES | DECIPHERA PHARMACEUTICALS, LLC (US) | 2014-09-18 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240317710-A1 | CRYSTALLINE CSF-1R INHIBITOR ACIDIC SALT, PREPARATION METHOD THEREFOR AND USE THEREOF | CSF1R, CSF3R, IL1RN | CSF1R 1/4885PDGFRA 808/4885PDGFRB 1105/4885 |
| US-20140275080-A1 | N-Acyl-N'-(pyridin-2-yl) Ureas and Analogs Exhibiting Anti-Cancer and Anti-Proliferative Activities | KIT, CSF1R, CSF3R | CSF1R 2/4885PDGFRA 5/4885PDGFRB 6/4885 |
| US-12435062-B2 | Amide compounds and uses thereof | ASNS, ASS1, NAT1 | CSF1R 2941/4885PDGFRA 3533/4885PDGFRB 3922/4885 |
| US-20140315917-A1 | IMIDAZOLIDINONES AND ANALOGS EXHIBITING ANTI-CANCER AND ANTI-PROLIFERATIVE ACTIVITIES | CSF1R, KIT, CSF3R | CSF1R 1/4885PDGFRA 5/4885PDGFRB 6/4885 |
| US-20250361223-A1 | AMIDE COMPOUNDS AND USES THEREOF | ASNS, NAT1, AADAC | CSF1R 3035/4885PDGFRA 3254/4885PDGFRB 3573/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.